Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2008

01-12-2008 | Breast Oncology

HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer

Authors: Dimosthenis Ziogas, MD, Eleftheria Ignatiadou, MD, Dimitrios Roukos, MD, Efstathios Lykoudis, MD

Published in: Annals of Surgical Oncology | Issue 12/2008

Login to get access

Excerpt

To the Editor: …
Literature
1.
Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133–44PubMedCrossRef
2.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER-2–positive breast cancer. N Engl J Med 2005;353:1659–72PubMedCrossRef
3.
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2–positive breast cancer. N Engl J Med 2005;353:1673–84PubMedCrossRef
4.
Roukos DH, Murray S, Briasoulis E Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMedCrossRef
5.
Roukos DH HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008;358:197PubMedCrossRef
6.
Kulkarni S, Hicks DG HER2-positive early breast cancer and trastuzumab: a surgeon’s perspective. Ann Surg Oncol 2008
7.
8.
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53PubMedCrossRef
9.
Roukos DH, Kappas AM, Agnantis NJ Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003;10:718–21PubMedCrossRef
10.
Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45PubMedCrossRef
11.
Roukos DH Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008;8:29–39PubMedCrossRef
12.
Roukos DH, Briasoulis E Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007;4:578–90PubMedCrossRef
13.
Fatouros M, Baltoyiannis G, Roukos DH The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2008;15:21–33PubMedCrossRef
14.
Agnantis NJ, Paraskevaidis E, Roukos D Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRef
15.
Roukos DH Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:1555–6PubMedCrossRef
16.
Liakakos T, Roukos DH More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008;15:956–60PubMedCrossRef
17.
18.
Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941–3PubMed
19.
Roukos DH, Kappas AM, Tsianos E Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002;9:607–9PubMedCrossRef
Metadata
Title
HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer
Authors
Dimosthenis Ziogas, MD
Eleftheria Ignatiadou, MD
Dimitrios Roukos, MD
Efstathios Lykoudis, MD
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-9973-3

Other articles of this Issue 12/2008

Annals of Surgical Oncology 12/2008 Go to the issue

Breast Oncology

The Intraductal Approach to Breast Cancer

Breast Oncology

The Role of Mammary Ductoscopy in Breast Cancer: a Review of the Literature

Endocrine Tumors

Surgical Approach and Perioperative Complications Determine Short-Term Outcomes in Patients with Insulinoma: Results of a Bi-Institutional Study

Breast Oncology

Surgical Decision-Making and the Influence of Biologic Markers: Reply

Other

Venous Thromboembolism in Cancer Patients Undergoing Major Surgery

Gastrointestinal Oncology

Improving the Accuracy of TNM Staging in Esophageal Cancer: A Pathological Review of Resected Specimens